<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">According to International Pharmaceutical Federation (FIP) guidance for pharmacists,
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> as a member of the healthcare professionals, it's one of the most essential responsibilities for hospital pharmacists to join the medical collaborative team and provide pharmaceutical care services to COVID-19 patients. For COVID-19 patients receiving centralized hospitalized treatment, pharmaceutical care services are indispensable supplement for clinical treatment and management, which is of great significance for improving the level of drug therapy, improving patient's outcome and promoting the overall pandemic control. Detailed and feasible suggestions on clinical diagnosis and treatment were provided in clinical management guidance from National Health Committee (NHC) of China, WHO, and Centers for Disease Control and Prevention (CDC) of the United States.
 <xref rid="bib7" ref-type="bibr">7</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref>, 
 <xref rid="bib9" ref-type="bibr">9</xref> However, it's worth mentioning that, most of the available guidance did not revolve detailed suggestions on therapeutic drugs or pharmaceutical care services. Currently, community pharmacists can provide strengthened pharmaceutical care and public health services following feasible instructions.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> However, for hospital pharmacists, recommendations and guidance on providing COVID-19 hospitalized patients with pharmaceutical care is still lacking, and need to be established urgently.
</p>
